NASDAQ:SCLX

Scilex Q3 2026 Earnings Date & Estimates

Scilex logo
$1.25 -0.18 (-12.59%)
Closing price 04:00 PM Eastern
Extended Trading
$1.25 +0.00 (+0.40%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Scilex is estimated to report Q3 2026 earnings on Wednesday, December 2, 2026, before market opens. The conference call is scheduled for November 27, 2026 at 4:00 PM ET.

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
4:00 PM ET

What Analysts Expect from Scilex in Q3 2026

Scilex is expected to post earnings of -$0.0756 per share on revenue of $17 million. In the same quarter a year earlier Scilex reported -$22.17 per share on revenue of $10.56 million. Scilex last reported on August 14, 2026, posting -$16.65 per share and missing the -$0.1813 consensus estimate. Scilex has beaten the consensus EPS estimate in 1 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.0756
Expected Revenue
$17 million
Prior-Year EPS
-$22.17
Prior-Year Revenue
$10.56 million
Expected Revenue Growth
+61.0%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$16.65 (Missed by -$16.4687)
Last Quarter Revenue
$7.64 million
EPS Beat Rate
1 of last 8 quarters

Scilex Q3 2026 Earnings FAQ

Scilex (NASDAQ:SCLX) is estimated to report Q3 2026 earnings on Wednesday, December 2, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Scilex's Q3 2026 earnings conference call is scheduled for Friday, November 27, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Scilex to post earnings of -$0.0756 per share for Q3 2026.

The consensus revenue estimate for Scilex is $17 million for Q3 2026.

Scilex Earnings Headlines

Scilex (NASDAQ:SCLX) Stock Price Down 8.3% - Here's Why
I'm handing you this one free
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.tc pixel
See More Scilex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scilex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scilex and other key companies, straight to your email.

About Scilex

Scilex (NASDAQ:SCLX) is a biopharmaceutical company focused on developing and commercializing treatments for pain and related conditions. Its portfolio includes therapies designed to offer alternatives to conventional pain-management approaches.

Its marketed products include ZTlido, a topical lidocaine system for pain associated with postherpetic neuralgia; Elyxyb, an oral celecoxib solution for acute migraine in adults; and GLOPERBA, an oral colchicine solution for preventing gout flares in adults. The company has also worked on investigational pain treatments, which are distinct from its approved products.

Scilex’s commercial operations are focused primarily on the United States. The company became publicly traded in 2022 through a business combination with Vickers Vantage Corp. I.

View Scilex Profile